IDL-2965: a selective, highly potent, clinical-stage integrin antagonist for treatment of non-alcoholic steatohepatitis

20204 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Journal of Hepatology

Volume 73, pp. S450-S450

Field-Weighted Citation Impact: 0.29